drugset
drugset / Trial / NCT03663751

Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

NCT03663751 ↗

Phase 2 Completed 14 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

Decreasing donor chimerism is considered as an early sign of graft failure or relapse in patients undergoing allogeneic stem cell transplantation. The treatment option included tapering or stop of immunosuppression and or donor lymphocyte infusion (DLI) which may restore a full donor chimerism but subsequent graft versus host disease (GVHD) is the major complications. In this single arm prospective study, the investigator evaluate the effect and safety of low-dose decitabine alone or with DLI in patients with decreased donor chimerism after allo-HSCT.

Timeline

Start
2018-07-01
Primary completion
2020-12-01
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 5 mg/m2 —

Indications

No indication recorded.